{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:14:39Z","timestamp":1787786079629,"version":"build-2784847793"},"reference-count":77,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Circulating tumor DNA (ctDNA) analysis has emerged as a powerful and minimally invasive approach for genomic profiling of metastatic castration-resistant prostate cancer (mCRPC), enabling real-time detection of tumor-derived mutations that guide therapy. Approximately 20% of mCRPC patients harbor alterations in homologous recombination repair (HRR) genes, most commonly BRCA1\/2 and ATM, which are actionable with different poly-(ADP-ribose) polymerase inhibitors (PARPIs) used as monotherapy or in combination with androgen receptor signaling inhibitors (ARSIs). A smaller subset of patients with mismatch repair deficiency (MMRd) or microsatellite instability-high (MSI-high) tumors may benefit from immune checkpoint blockade with pembrolizumab. Different FDA-approved liquid biopsy assays detect these actionable alterations when tissue biopsies are unavailable or insufficient. This review summarizes current evidence on ctDNA-based genotyping in mCRPC, highlighting clinically actionable mutations, corresponding targeted therapies, and technical and analytical considerations for clinical implementation. By capturing DNA shed from multiple metastatic sites, ctDNA profiling provides a comprehensive view of tumor heterogeneity and enables serial monitoring of molecular evolution. Overall, ctDNA analysis represents a transformative advance in precision oncology, supporting personalized treatment selection and ongoing assessment of therapeutic response in mCRPC.<\/jats:p>","DOI":"10.3390\/curroncol32120692","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:30:07Z","timestamp":1765207807000},"page":"692","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of Actionable Mutations in Metastatic Castration-Resistant Prostate Cancer Through Circulating Tumor DNA: Are We There Yet?"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2396-9829","authenticated-orcid":false,"given":"Wensi","family":"Tao","sequence":"first","affiliation":[{"name":"Department of Medical Education, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Sabel","sequence":"additional","affiliation":[{"name":"Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1605-8317","authenticated-orcid":false,"given":"R. Daniel","family":"Bonfil","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/brv.12413","article-title":"The diverse origins of circulating cell-free DNA in the human body: A critical re-evaluation of the literature","volume":"93","author":"Aucamp","year":"2018","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: Towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"224ra224","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.18632\/oncoscience.592","article-title":"Evolving insights in blood-based liquid biopsies for prostate cancer interrogation","volume":"10","author":"Bonfil","year":"2023","journal-title":"Oncoscience"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrc.2016.35","article-title":"Defining actionable mutations for oncology therapeutic development","volume":"16","author":"Carr","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.urology.2016.06.011","article-title":"Predictors of Time to Metastasis in Castration-resistant Prostate Cancer","volume":"96","author":"Moreira","year":"2016","journal-title":"Urology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41391-018-0121-2","article-title":"Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry","volume":"22","author":"Francini","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s11912-024-01614-6","article-title":"Prostate Cancer, Pathophysiology and Recent Developments in Management: A Narrative Review","volume":"26","author":"Almeeri","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO-24-02608","article-title":"Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline","volume":"43","author":"Yu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2020.12.039","article-title":"Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians","volume":"79","author":"Merseburger","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41585-021-00455-3","article-title":"Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer","volume":"18","author":"Ng","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"djx118","DOI":"10.1093\/jnci\/djx118","article-title":"Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer","volume":"109","author":"Wyatt","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","article-title":"Genomic Analysis of Circulating Tumor DNA in 3334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms","volume":"27","author":"Tukachinsky","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13073-018-0595-5","article-title":"Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis","volume":"10","author":"Mayrhofer","year":"2018","journal-title":"Genome Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_19","first-page":"djv098","article-title":"A decision support framework for genomically informed investigational cancer therapy","volume":"107","author":"Johnson","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Maloberti, T., De Leo, A., Coluccelli, S., Sanza, V., Gruppioni, E., Altimari, A., Zagnoni, S., Giunchi, F., Vasuri, F., and Fiorentino, M. (2023). Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1\/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108940"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrg2380","article-title":"Single-strand break repair and genetic disease","volume":"9","author":"Caldecott","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Nussenzweig","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2016.311","article-title":"PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: Current practice and future directions","volume":"115","author":"Konecny","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.32604\/or.2023.028310","article-title":"Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials","volume":"31","author":"Nambiar","year":"2023","journal-title":"Oncol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-genet-110410-132435","article-title":"Double-strand break end resection and repair pathway choice","volume":"45","author":"Symington","year":"2011","journal-title":"Annu. Rev. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10524","DOI":"10.1074\/jbc.TM118.000372","article-title":"Homologous recombination and the repair of DNA double-strand breaks","volume":"293","author":"Wright","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s12276-020-00519-1","article-title":"DNA end resection and its role in DNA replication and DSB repair choice in mammalian cells","volume":"52","author":"Zhao","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Carusillo, A., and Mussolino, C. (2020). DNA Damage: From Threat to Treatment. Cells, 9.","DOI":"10.3390\/cells9071665"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.18632\/oncotarget.28015","article-title":"Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): Challenges and solutions","volume":"12","author":"Scott","year":"2021","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sorrentino, C., and Di Carlo, E. (2023). Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges. Cancers, 15.","DOI":"10.3390\/cancers15112885"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Valsecchi, A.A., Dionisio, R., Panepinto, O., Paparo, J., Palicelli, A., Vignani, F., and Di Maio, M. (2023). Frequency of Germline and Somatic. Cancers, 15.","DOI":"10.3390\/cancers15092435"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_38","unstructured":"NCCN (2025, April 30). National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Prostate Cancer Version 2. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.eururo.2020.09.024","article-title":"Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib","volume":"79","author":"Stopsack","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/tcr-23-1563","article-title":"How far does a new horizon extend for rucaparib in metastatic prostate cancer?","volume":"13","author":"Karzai","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in Men with Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): Final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.23.01868","article-title":"FDA Approval Summary: Olaparib in Combination with Abiraterone for Treatment of Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer","volume":"42","author":"Fallah","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial","volume":"8","author":"Chi","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: Final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s43018-024-00894-y","article-title":"Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: Updated results of the KEYNOTE-158 trial","volume":"6","author":"Marabelle","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.euo.2025.04.025","article-title":"PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes","volume":"8","author":"Rescigno","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Milbury, C.A., Creeden, J., Yip, W.K., Smith, D.L., Pattani, V., Maxwell, K., Sawchyn, B., Gjoerup, O., Meng, W., and Skoletsky, J. (2022). Clinical and analytical validation of FoundationOne(R)CDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264138"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s44276-024-00049-7","article-title":"Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project","volume":"2","author":"Shiota","year":"2024","journal-title":"BJC Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1158\/1078-0432.CCR-21-3577","article-title":"Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA","volume":"29","author":"Matsubara","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.05.005","article-title":"Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer","volume":"67","author":"Efstathiou","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-19-1324","article-title":"Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel","volume":"25","author":"Willis","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2147\/OTT.S285758","article-title":"Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer","volume":"15","author":"Jang","year":"2022","journal-title":"Onco Targets Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e001065","DOI":"10.1136\/jitc-2020-001065","article-title":"Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA","volume":"8","author":"Barata","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_66","unstructured":"FDA (2025, September 10). FoundationOne Liquid CDx\u2014P190032, Available online: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf19\/P190032S011A.pdf."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41525-023-00374-9","article-title":"Clinically significant germline pathogenic variants are missed by tumor genomic sequencing","volume":"8","author":"Stout","year":"2023","journal-title":"NPJ Genom. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Piombino, C., Pipitone, S., Tonni, E., Mastrodomenico, L., Oltrecolli, M., Tchawa, C., Matranga, R., Roccabruna, S., D\u2019Agostino, E., and Pirola, M. (2024). Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25094624"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"11769351221076062","DOI":"10.1177\/11769351221076062","article-title":"Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer","volume":"21","author":"Hirahata","year":"2022","journal-title":"Cancer Inform."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Bang, S., Won, D., Shin, S., Cho, K.S., Park, J.W., Lee, J., Choi, Y.D., Kang, S., Lee, S.T., and Choi, J.R. (2023). Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression. Cancers, 15.","DOI":"10.3390\/cancers15153998"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Gonzalez Caldito, N. (2023). Role of tumor necrosis factor-alpha in the central nervous system: A focus on autoimmune disorders. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1213448"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kwan, E.M., Wyatt, A.W., and Chi, K.N. (2022). Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1054497"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","article-title":"Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation","volume":"30","author":"Rolfo","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.trecan.2021.06.001","article-title":"Technical and biological constraints on ctDNA-based genotyping","volume":"7","author":"Herberts","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamaoncol.2020.5161","article-title":"Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference","volume":"7","author":"Jensen","year":"2021","journal-title":"JAMA Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/12\/692\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:04:31Z","timestamp":1765209871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/12\/692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":77,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["curroncol32120692"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32120692","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}